<DOC>
	<DOCNO>NCT01804634</DOCNO>
	<brief_summary>The purpose study see give reduce intensity chemotherapy , haploidentical bone marrow , post-transplant cyclophosphamide sirolimus safe feasible patient high-risk solid tumor .</brief_summary>
	<brief_title>A Phase II Trial Reduced Intensity Conditioning Haploidentical BMT High-risk Solid Tumors</brief_title>
	<detailed_description>Allogeneic hematopoietic stem cell transplantation ( HSCT ) may associate clinically significant `` graft-versus-tumor '' ( GVT ) effect , even disease unresponsive chemotherapy radiation therapy . Graft-vs.-tumor ( GVT ) effect describe allogeneic HCT neuroblastoma , Ewing sarcoma , osteosarcoma , rhabdomyosarcoma , melanoma hepatoblastoma . Our goal maximize T cell NK cell mediate graft versus tumor effect poor prognosis solid tumor patient use haploidentical donor , T cell replete bone marrow , unique post-transplant immunosuppression regimen contain post transplantation Cy mTOR inhibitor . This therapy widely applicable almost patient half-matched donor available ( parent sibling ) . We hope demonstrate safety feasibility therapy anticipation combine platform additional post-transplantation therapy cryoablation , Donor Lymphocyte Infusion ( DLI ) , stem cell direct therapy , immunologic checkpoint inhibitor , and/or metabolic inhibitor .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Patients must HLAmismatched , relate donor ( 3/6 5/6 i.e. , 3 6 antigen match ) . Patients inherited recombinant HLA haplotype may receive marrow parent whose gamete recombination occur . Sarcoma patient : Males Females &lt; 40 year age . All diagnosis : Males Females &lt; 21 year age Patients must confirm histopathologic diagnosis classify high risk define expect survival &lt; 10 % . Examples include : Neuroblastoma ganglioneuroblastoma ( Failure achieve least PR induction therapy COG ANBL0532 standard chemotherapy ; Refractory induction chemotherapy standard chemotherapy ; Patients high risk disease define Appendix 1 whose autologous peripheral blood stem cell product contaminate neuroblastoma autologous product available ; Patients high risk disease meet eligibility requirements/organ function requirement myeloablative conditioning ; Patients &gt; 5 identified lesion end induction MIBG scan Stage 4 rhabdomyosarcoma Metastatic Ewing Sarcoma Osteosarcoma metastatic disease beyond lung and/or lung metastasis amenable resection Hepatoblastoma amenable resection Metastatic Melanoma Desmoplastic small round cell tumor Brain tumor astrocytic tumor , oligodendroglial tumor , ependymal tumor , choroid plexus tumor , neuroepithelial tumor , neuronal mixed neuronalglial tumor , tumor pineal region , embryonic tumor Any solid tumor soft tissue sarcoma estimate &lt; 10 % chance survival consider case case basis departmental tumor board and/or sarcoma meeting Previous therapy : It expect patient receive upfront standard care therapy respect disease Patients relapse either single tandem autologous BMT eligible ( &gt; 6 month must elapse start last BMT ) . Patients must recover acute toxicity prior chemo/radio/immunotherapy BMT Patients need measurable disease time enrollment . Patients measurable disease must stable disease RECIST criterion two scan least 4 week apart . Patients adequate organ function measure : Cardiac : Left ventricular ejection fraction rest must ≥ 35 % , shorten fraction &gt; 25 % . Hepatic : Bilirubin ≤ 3.0 mg/dL ; ALT , AST , Alkaline Phosphatase &lt; 5 x ULN . Renal : Serum creatinine within normal range age , serum creatinine outside normal range age , renal function ( creatinine clearance GFR ) &gt; 40 mL/min/1.73m2 . Pulmonary : FEV1 , FVC , DLCO ( diffusion capacity ) &gt; 50 % predict ( correct hemoglobin ) ; unable perform pulmonary function test , O2 saturation &gt; 92 % room air . Good performance status ( Karnofsky/Lansky 70100 ) Patients ( Parents/guardians &lt; 18 ) donor must able sign consent form . Patients must willing participate stage treatment Criteria donor eligibility : Age &gt; 0.5 year Donors must meet selection criterion define Foundation Accreditation Hematopoietic Cell Therapy ( FACT ) . Lack recipient antidonor HLA antibody Note : In instance , low level , noncytotoxic HLA specific antibody may permissible find level well detectable flow cytometry . This decide casebycase basis PI one immunogenetics director . In event two eligible donor identify , follow order priority use determine preferred donor : 1 . Medically psychologically fit willing donate 2 . Killer Immunoglobulin Receptor ( KIR ) Haplotype B Donor 3 . Red bloodcell compatibility ( order preference ) 1 . RBC crossmatch compatible 2 . Minor ABO incompatibility 3 . Major ABO incompatibility For CMV seronegative recipient , CMV seronegative donor . For CMV seropositive recipient , CMV seropositive donor prefer . If one prefer donor identify list medical reason prefer one , follow guideline recommend : 1 . If patient male , choose male donor 2 . Choose young prefer donor 3 . If patient family express strong preference particular donor , use one Patients excluded basis sex , racial ethnic background . HIVpositive Donor ( donor antirecipient ) ABO incompatibility ABO compatible donor available . Positive leukocytotoxic crossmatch Women childbearing potential currently pregnant practice adequate contraception Uncontrolled viral , bacterial , fungal infection .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Solid Tumors</keyword>
	<keyword>Neuroblastoma</keyword>
	<keyword>Osteosarcoma</keyword>
	<keyword>Ewing Sarcoma</keyword>
	<keyword>Rhabdomyosarcoma</keyword>
	<keyword>Hepatoblastoma</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Desmoplastic Round Cell Tumor</keyword>
	<keyword>brain tumor</keyword>
</DOC>